KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
16 February 2023 - 10:30PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced the acceptance of multiple abstracts at the 2023
Annual Scientific Meeting for the American Academy of Allergy,
Asthma & Immunology taking place in San Antonio, Texas from
February 24-27. All results will be shared as a poster presentation
and Q&A on Sunday, February 26 from 9:45-10:45 a.m. CST in the
Convention Center, Lobby Level, Hall 2.
- Treatment with Sebetralstat Reduces the Cumulative Symptom
Severity of Hereditary Angioedema Attacks in a Phase 2 Trial
(Poster # 401): Jonathan A. Bernstein, Marc A. Riedl,
William R. Lumry, Paul K. Audhya, Michael D. Smith, Christopher M.
Yea.
- A Comparative Bioavailability of Sebetralstat Following
Administration of Orally Disintegrating Tablets and Film-Coated
Tablets in Healthy Volunteers (Poster #430): Michael D.
Smith, Matt Iverson, Erik Hansen, Paul K. Audhya, Christopher M.
Yea.
- Anxiety Associated With Parenteral On-demand Treatment For
Hereditary Angioedema (HAE) (Poster #433): Autumn
Burnette, John Anderson, Hilary Longhurst, Sally van Kooten, Markus
Heckmann, Sherry Danese, Ledia Goga.
- Patient Perspectives On Early Use Of On-demand Treatment For
Hereditary Angioedema (HAE) Attacks to Reduce Severity and Duration
(Poster #437): Cristine Radojicic, Michael Manning, Mar
Guilarte, Markus Heckmann, Sally van Kooten, Sherry Danese, Ledia
Goga.
- Reporting of Adverse Drug Reactions with Parenteral Drugs
for the On-Demand Treatment of Hereditary Angioedema Attacks –
Analysis of the FAERS Database 2009 to 2022 (Poster
#442): Raffi Tachdjian, Sinisa Savi, Moshe Fridman, Joao
Frade, Paul K. Audhya, Marie Fasehun.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista is developing sebetralstat as an
oral on-demand therapy for HAE attacks and is enrolling the Phase 3
KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa
inhibitor program represents a new generation of therapies that may
further improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
For more information on the sebetralstat HAE on-demand Phase 3
KONFIDENT study, please visit www.konfidentstudy.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and its results, our ability to commence clinical
studies or complete ongoing clinical studies, including our Phase 3
KONFIDENT trial, and to obtain regulatory approvals for
sebetralstat and other candidates in development, the success of
any efforts to commercialize sebetralstat, the ability of
sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2022, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230216005201/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024